Retacrit epoetin zeta: Postmarketing study data

Hospira reported that the prospective, postmarketing European ORHEO trial in 2,310 adults with solid tumors, lymphomas and myelomas showed that Retacrit epoetin zeta met the primary endpoint of hemogl...